Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Current Liabilities (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Total Current Liabilities for 15 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 7.86% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Oct 2025, down 7.86%, and an annual FY2025 reading of $1.7 million, down 7.86% over the prior year.
  • Total Current Liabilities was $1.7 million for Q4 2025 at Pharma-Bio Serv, up from $1.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $5.5 million in Q1 2021 and bottomed at $1.7 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $2.5 million, with a median of $2.2 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 184.4% in 2021, then plummeted 58.05% in 2022.
  • Year by year, Total Current Liabilities stood at $2.7 million in 2021, then dropped by 21.03% to $2.1 million in 2022, then rose by 2.18% to $2.2 million in 2023, then fell by 12.37% to $1.9 million in 2024, then fell by 7.86% to $1.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for PBSV at $1.7 million in Q4 2025, $1.7 million in Q3 2025, and $1.8 million in Q2 2025.